Contrasting BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)

Enlivex Therapeutics (NASDAQ:ENLV) and BioStem Technologies (OTCMKTS:BSEM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Insider and Institutional Ownership

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Enlivex Therapeutics and BioStem Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
BioStem Technologies	N/A	N/A	N/A

Volatility & Risk

Enlivex Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, BioStem Technologies has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.

Earnings and Valuation

This table compares Enlivex Therapeutics and BioStem Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24 billion	($8.25)	-0.18
BioStem Technologies	$292.21 million	0.19	-$28.56 million	($1.60)	-1.98

Enlivex Therapeutics has higher earnings, but lower revenue than BioStem Technologies. BioStem Technologies is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Enlivex Therapeutics and BioStem Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1	1	1	1	2.50
BioStem Technologies	0	1	0	1	3.00

Enlivex Therapeutics currently has a consensus target price of $247.50, indicating a potential upside of 16,301.59%. BioStem Technologies has a consensus target price of $9.00, indicating a potential upside of 184.81%. Given Enlivex Therapeutics’ higher possible upside, equities analysts clearly believe Enlivex Therapeutics is more favorable than BioStem Technologies.

Summary

Enlivex Therapeutics beats BioStem Technologies on 9 of the 12 factors compared between the two stocks.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.